Malignant tumor (except leukemia)
Conditions
Sponsors
Tanigawa Keishi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients must: - have ECOG Performance Status for 0, 1 or 2. - maintain adequate function of key organs when the eligibility is confirmed, in particular: 1. haemoglobin 8.0 g/dl or more 2. platelet 50.000 /mm3 or more 3. total bilirubin 3 x ULN or more 4. AST/ALT 3 x ULN or less 5. creatinine 3 x ULN or less - provide written consent for treatment of neoantigens-loaded DC vaccination. - have a proper mental condition and an ability to recognize the object and contents of the study when informed consent is obtained.
Exclusion criteria
Exclusion criteria: Patients must not: - be impossible to obtain blood sample by Leukapeheresis. - be positive in HIV antibody test. - have active auto-immune disorder. - have serious underlying disease. - be pregnant (including pregnancy seeker) - be judged ineligibles by clinician in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Delayed type hypersensitivity reaction at the injection site of neoantigen peptides-loaded dendritic cell vaccine | — |
Countries
Japan
Contacts
Public ContactYasunobu Kobayashi
BioThera Clinic
Outcome results
None listed